Images List Premium Download Classic

Obesity

Obesity-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Pharmaceutical composition for preventing and treating obesity or liver diseases, containg tlr7 agonist
Knotus Life Science Inc.
June 14, 2018 - N°20180161318

The present invention is based on the fact that imiquimod, which is a substance that enhances toll-like receptor 7 (tlr7) related to the innate immunity of a living body, is effective in the prevention and treatment of obesity or liver disease, and the present invention relates to a pharmaceutical composition for the prevention and treatment of obesity or liver disease, wherein ...
Nutritional compositions containing butyrate and uses thereof
Mead Johnson Nutrition Company
June 14, 2018 - N°20180160714

Provided are nutritional compositions containing dietary butyrate. Further disclosed are methods for reducing the incidence of obesity and metabolic syndrome in a target subject via administering the nutritional composition containing dietary butyrate to the target subject.
Compounds as peptidic glp1/glucagon/gip receptor agonists
Sanofi
June 07, 2018 - N°20180155407

The present invention relates to trigonal glp-1/glucagon/gip receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.. .
Obesity Patent Pack
Download 316+ patent application PDFs
Obesity Patent Applications
Download 316+ Obesity-related PDFs
For professional research & prior art discovery
inventor
  • 316+ full patent PDF documents of Obesity-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Therapies for obesity, diabetes and related indications
Palatin Technologies, Inc.
June 07, 2018 - N°20180153965

The invention relates to methods, uses, compositions and formulations including a melanocortin receptor-4 agonist and a glucagon-like peptide-1 receptor agonist for treatment of obesity, diabetes, metabolic syndrome and related indications, diseases or disorders.. .
Methods for treating overweight or obesity
Gelesis, Llc
June 07, 2018 - N°20180153925

The present invention relates to methods of managing weight, and treating overweight or obesity and treating or preventing diabetes in a subject in need thereof. In one embodiment, the method comprises the steps of (a) orally administering to the subject from about 0.7 g to about 4 g of crosslinked carboxymethylcellulose; and (b) orally administering to the subject at least about 100 ml ...
Methods and compositions for treating diabetes, metabolic syndrome and other conditions
Cortendo Ab (publ)
June 07, 2018 - N°20180153883

Pharmaceuticals compositions comprising the 2s, 4r, ketoconazole enantiomer or its pharmaceutically acceptable salts, hydrates, and solvates, that are substantially free of the 2r, 4s ketoconazole enantiomer are useful to reduce cortisol synthese and for the treatment of type 2 diabetes, hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, metabolic syndrome, and other diseases and conditions, including but not limited to cushing's syndrome, ...
Obesity Patent Pack
Download 316+ patent application PDFs
Obesity Patent Applications
Download 316+ Obesity-related PDFs
For professional research & prior art discovery
inventor
  • 316+ full patent PDF documents of Obesity-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Method of epigenetic analysis for determining clinical genetic risk
The Johns Hopkins University
May 31, 2018 - N°20180148783

The present invention provides a method for identifying a subject having or at risk of having a metabolic disease, such as diabetes or obesity. The invention is based on an approach to identify candidate genes involved in metabolic diseases, such as obesity and type 2 diabetes (t2d) through epigenetic mechanisms.
Combination compositions and their use in methods for treating obesity and obesity-related disorders
Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (gmbh)
May 31, 2018 - N°20180147163

The present invention relates to compositions comprising at least two different active compounds and the use of such combination compositions in medicine, in particular in methods for treating obesity and obesity-related disorders and/or in methods for inhibiting weight gain.. .
Acylated glucagon analogues
Zealand Pharma A/s
May 24, 2018 - N°20180141990

The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods.
Autotaxin inhibitors and uses thereof
National And Kapodistrian University Of Athens
May 24, 2018 - N°20180141965

Novel inhibitors of the enzyme autotaxin are described. The inhibitors contain one or two zinc-binding groups at the appropriate distance, also described are uses thereof, such as for the inhibition of autotaxin activity and the treatment of various conditions (e.g., inflammatory conditions, cancer, obesity, autoimmune diseases)..
Method of treating focal segmental glomerulosclerosis
Chemocentryx, Inc.
May 24, 2018 - N°20180140587

A method of treating focal segmental glomerulosclerosis with a compound of formula i is provided. Fsgs may be primary (no known cause) or secondary.
Adipocyte-derived exosomes, and compositions, kits, and methods of using the same for detection and screening
Children's National Medical Center
May 17, 2018 - N°20180136230

The invention relates to isolation of adipocyte-derived exosomes from a biological sample, as well as methods, compositions and kits for detecting an obesity-related disorder, for detecting risk of having an obesity-related disorder, for screening or identifying a therapy for an obesity-related disorder, for screening or identifying a therapeutic agent for an obesity-related disorder, and for treating or preventing an obesity-related ...
Methods of treating obesity with anti-angptl8 antibodies
Regeneron Pharmaceuticals, Inc.
May 17, 2018 - N°20180134781

The present invention provides antibodies that bind to angptl8 and methods of using the same. According to certain embodiments, the invention includes methods of using anti-angptl8 antibodies that bind human angptl8 with high affinity to treat obesity, reduce body fat, reduce body weight, increase energy expenditure, and increase hdl-c, in a subject..
Obesity Patent Pack
Download 316+ patent application PDFs
Obesity Patent Applications
Download 316+ Obesity-related PDFs
For professional research & prior art discovery
inventor
  • 316+ full patent PDF documents of Obesity-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
A method for predicting the risk of incidence of chronic kidney diseases
Sphingotec Gmbh
May 10, 2018 - N°20180128838

The present invention relates to means and methods suitable for risk prediction of chronic kidney disease (ckd) using pro-enkephalin or fragments thereof as biomarker. The risk prediction methods of the invention are intended for healthy subjects and for subjects suffering from diseases such as hypertension, cardiovascular diseases and events, diabetes, metabolic syndrome, obesity, or autoimmune diseases.
Methods for controlling obesity using minimally invasive means
May 10, 2018 - N°20180127756

Methods for controlling obesity using minimally-invasive procedures including introducing embolic crystal particles that are naturally occurring and mostly non-toxic salts into the arterial capillaries feeding the sections of the stomach where the appetite inducing hormone, ghrelin, is produced to limit the blood flow to the region reducing appetite; introducing a virus vector or antisense oligonucleotide to inhibit the production of ...
Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide y receptors
May 10, 2018 - N°20180127476

Z4, z7, z9, z11, z22, z23, z26, z30, z34, z35, p, m, n, q, and bridge are defined in the specification. The invention also relates to pharmaceutical compositions and methods for use thereof.
Eckol derivatives, methods of synthesis and uses thereof
Phloronol, Inc.
May 10, 2018 - N°20180127392

Provided herein are eckol derivatives, methods of synthesis thereof and pharmaceutical compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, alzheimer's disease, microbial infections, obesity, diabetes, cancer or inflammation using the compounds and pharmaceutical compositions disclosed herein..
Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives
Reviva Pharmaceuticals, Inc.
May 10, 2018 - N°20180127362

The present invention provides novel phenylcycloalkylmethylamine derivatives, and methods of preparing phenylcycloalkylmethylamine derivatives. The present invention also provides methods of using phenylcycloalkylmethylamine derivatives and compositions of phenylcycloalkylmethylamine derivatives.
Human catestatin induces gut microbiota dysbiosis
University Of Manitoba
May 10, 2018 - N°20180125927

Treatment with catestatin changes the proportion of two major phyla bacteroidetes and firmicutes in the gut microbiota in an opposite manner observed in intestinal disorders like ibd, ibs or non-intestinal disorders like obesity. Specifically, administration of an effective amount of catestatin increased the relative percentage of bacteroidetes and decreased the relative percentage of firmicutes in the gut microbiota..
Composition for preventing or treating bone disease, obesity and lipid-related metabolic disease
Cell Biotech Co., Ltd.
May 10, 2018 - N°20180125901

The present invention relates to a functional composition for preventing, alleviating or treating bone disease and lipid-related metabolic disease, and more particularly to a composition which comprises a combination of probiotics and a vitamin complex, which is capable of effectively preventing, alleviating or treating bone disease, obesity and lipid-related metabolic disease by synergistic effects on antioxidant activity, a reduction in ...
Loading